Novartis to Acquire AveXis, Expand Position in Gene Therapy
- Posted by ISPE Boston
- On April 16, 2018
Novartis has announced that it has entered into an agreement to acquire the Illinois-based clinical stage gene therapy company AveXis, Inc. for $218 per share or a total of $8.7 billion in cash. AveXis has several clinical studies in progress for the treatment of SMA, an inherited neurodegenerative disease caused by a defect in a […]
Read More